2023
Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sample
2022
Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis
Radhakrishnan R, Pries LK, Erzin G, Have M, de Graaf R, van Dorsselaer S, Gunther N, Bak M, Rutten BPF, van Os J, Guloksuz S. Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis. Psychological Medicine 2022, 53: 5551-5557. PMID: 36093677, PMCID: PMC10482707, DOI: 10.1017/s0033291722002756.Peer-Reviewed Original ResearchConceptsAnxiety/depressive symptomsDepressive symptomsCannabis usePE incidencePsychotic experiencesFirst longitudinal cohort studyNetherlands Mental Health SurveyLongitudinal cohort studyMental Health SurveyRole of cannabisBidirectional relationshipCohort studyHealth SurveyIncidence studyAffective symptomsSymptomsCannabisEducation statusLongitudinal studyPsychosisIncidenceAnxietyTemporal relationshipMediation analysisFurther support
2021
Longitudinal associations between alcohol use, smoking, genetic risk scoring and symptoms of depression in the general population: a prospective 6-year cohort study
de Boer N, Vermeulen J, Lin B, van Os J, Have M, de Graaf R, van Dorsselaer S, Bak M, Rutten B, Batalla A, Guloksuz S, Luykx J. Longitudinal associations between alcohol use, smoking, genetic risk scoring and symptoms of depression in the general population: a prospective 6-year cohort study. Psychological Medicine 2021, 53: 1409-1417. PMID: 35023464, PMCID: PMC10009403, DOI: 10.1017/s0033291721002968.Peer-Reviewed Original ResearchConceptsNumber of cigarettesDepressive symptomsAlcohol useLongitudinal associationsGeneral populationSmoking behaviorAlcohol consumptionGenetic risk scoringSymptoms of depressionGenetic risk score analysisGenetic risk scoreAlcohol cessationCohort studySmoking statusGlobal burdenMood disordersRisk scoreSmokingModerate drinkingRisk score analysisLess symptomsLinear mixed effects modelsSymptomsScore analysisRisk scoring
2020
Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway
van Os J, Pries L, Have M, de Graaf R, van Dorsselaer S, Delespaul P, Bak M, Kenis G, Lin B, Luykx J, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine 2020, 52: 1910-1922. PMID: 33070791, DOI: 10.1017/s0033291720003748.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersChildhood adversityRisk factorsNEMESIS-2Affective dysregulationNon-genetic risk factorsSignificant depressive symptomsSample of patientsRepresentative general population sampleGenetic risk factorsGeneral population sampleSchizophrenia polygenic riskPsychosis outcomesSpectrum disorderDepressive symptomsPRS-SZPolygenic riskDysregulationPatientsPopulation samplePsychosisAffective pathwayDisordersHallucinatory experiencesDelusional ideationS115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS
Bor E, Quattrone D, Rodriguez V, Alameda L, Guloksuz S, Murray R. S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin 2020, 46: s78-s78. PMCID: PMC7234345, DOI: 10.1093/schbul/sbaa031.181.Peer-Reviewed Original ResearchLength of hospitalisationCase-control studyClinical outcomesFunctional outcomeClinical utilityDepressive symptomsSymptom dimensionsPositive symptomsNegative symptomsGlobal functioningFirst-episode psychosis patientsMulticentre case-control studyBaseline positive symptomsLong-Term ClinicalRisk of hospitalisationEpisode psychosis patientsPoor clinical outcomeFirst-episode psychosisCurrent clinical utilityPotential clinical utilitySymptom-based approachFurther outcome researchHospital admissionBetter prognosisProspective study
2013
Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability
Guloksuz S, Wichers M, Kenis G, Russel M, Wauters A, Verkerk R, Arts B, van Os J. Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability. PLOS ONE 2013, 8: e60435. PMID: 23544139, PMCID: PMC3609785, DOI: 10.1371/journal.pone.0060435.Peer-Reviewed Original ResearchConceptsCrohn's diseaseDisease activityImmune activationDepressive symptomsDepression scoresTrp availabilityΑ treatmentTryptophan availabilityNegative APPsAnti-tumor necrosis factorPast depressive disorderTNF-α treatmentSymptoms of depressionQuality of lifeCD patientsIBDQ scoreImmune markersComorbid depressionDepressive disorderNecrosis factorInflammatory reactionPatientsSymptomsDiseaseTreatment